InsiderInsights Daily Ratings Report: January 23, 2023
InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
Consumer Portfolio Service is a finance company. The company's primary business is to purchase and service retail automobile contracts originated primarily by franchised automobile dealers and select independent dealers in the United States in the sale of new and used automobiles, light trucks and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers who have limited credit histories or past credit problems, who the company refers to as sub-prime customers. The company provides eight different financing programs: Bravo, First Time Buyer, Mercury / Delta, Standard, Alpha, Alpha Plus, Super Alpha and Preferred.
MacroGenics discovers and develops antibody-based therapeutics to modulate the human immune response for the treatment of cancer. The company has a pipeline of product candidates in human clinical testing, including immuno-oncology programs, that have been created using its proprietary antibody-based technology platforms. The company is developing product candidates that target various tumor-associated antigens, including HER2. The company is also developing a franchise of molecules that target programmed cell death protein 1 (PD-1). The company is developing two bispecific DART product candidates that engage PD-1 and lymphocyte-activation gene 3, as well as PD-1 and cytotoxic T-lymphocyte-associated protein 4.
NGM Biopharmaceuticals is a biopharmaceutical company. The company is focused on the following programs: Aldafermin, which is for the treatment of non-alcoholic steatohepatitis (NASH); NGM313 (MK-3655), which is for the treatment of NASH and type 2 diabetes; NGM120, which is designed to block the effects of elevated growth differentiation factor 15 levels on cancer anorexia/cachexia syndrome, and, possibly, tumors; NGM217, which is designed to restore pancreatic islet function and increase insulin production in patients with diabetes; NGM621, which is designed to decrease levels of this protein implicated in the dry form of AMD; and NGM395, which is for the treatment of metabolic syndrome.
Insiderinsights' advanced insider analytics combine statistical track records with numerous behavioral metrics to rate the significance of a firm's insider trading history in real time.
Academic studies and the experience of professionals back the common sense conclusion that the Form 4 data filed daily at the SEC is a profitable data stream to mine for investment intelligence. But most investors use commodity insider feeds that are full of noise and time-consuming to analyze, or ratings services that employ last century's simplistic insider scoring methodology.
InsiderInsights compiles Daily, Weekly, and Monthly reports that list US equities with recent insider activity, along with proprietary Company Ratings clearly indicating the Significance Level of insider sentiment. Our monthly Special Screens further combine our Ratings with various fundamental and price action criteria, to highlight the best value, growth, momentum, and short ideas coming from the executive suite.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.